2018) and induces the expression of TNF-α, IL-1β, and IL-6 (Fang et al. 2019). NF-κB inhibitors significantly reduce the infiltration of inflammatory cells and repress the expression of TNF-α, IL-6, and other inflammatory cytokines. NF-κB inhibitors effectively reduce the inflammatory response of colonic tissue, supporting the pivotal role of NF-κB in the occurrence and development of IBD (Samman et al. 2018; Güvenç et al. 2019). This evidence concerns the gene NFKB1 and inflammatory bowel disease.